Centre National De La Recherche Scientifique

Universitè De Montpellier

Instytut Farmakologii Polskiej Akademii Nauk

Uniwersyter Jagiellonski

Uniwersytet Jagiellonski

Tomasz Kos

Jean Martinez

Gilles Subra

Frédéric Lamaty

Maciej Pawlowski

Grzegorz Satala

Pawel Zajdel

Anna Wesolowska

Andrzej J Bojarski

Piotr Popik

Evelina Colacino

Anna Partyka

Xavier Bantreil

Katarzyna Grychowska

Wesolowska Anna

This invention concerns pyrroloquinoline derivatives as antagonists of 5-HT6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in schizophrenia, anxiety, depression, maniac depression, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, panic attacks, attention deficit hyperactivity disorder, attention deficit disorder, Parkinson's disease, Huntington's disease, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, obesity and type-2 diabetes, functional bowel disorder, Irritable Bowel Syndrome. The compounds have the general formula (XIV), wherein the symbols have the meanings given in the description.

[object Object]

Growing community of inventors

Kraków, Poland

Tomasz Kos